Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | CCNK | O75909 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CCND3 | P30281 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4033700 | 0.82 | ALDH1A1 (0.57) | MAPK10MEN1KMT2AGFERNPC1 | |
| SCHEMBL17713569 | 0.81 | RET (0.56) | NPC1RAB9AMAPTTNIKSMN1; SMN2 | |
| SCHEMBL18199830 | 0.79 | MEN1 (0.67) | MAPK10MEN1KMT2AGFERNPC1 | |
| SCHEMBL31220877 | 0.79 | MAPK10 (0.73) | MAPK10MEN1KMT2AGFERNPC1 | |
| SCHEMBL7941542 | 0.79 | MAPK10 (0.73) | MAPK10MEN1KMT2AGFERNPC1 | |
| SCHEMBL6836695 | 0.77 | MAPK10 (0.55) | MAPK10MEN1KMT2AGFERNPC1 | |
| SCHEMBL9777679 | 0.77 | MEN1 (0.55) | MAPK10MEN1KMT2AGFERNPC1 | |
| SCHEMBL1600227 | 0.77 | MEN1 (0.50) | MAPK10MEN1KMT2AGFERNPC1 | |
| SCHEMBL3642226 | 0.77 | MAPK10 (0.51) | MAPK10MEN1KMT2AGFERNPC1 | |
| SCHEMBL8335509 | 0.75 | MAPT (0.51) | MAPK10MEN1KMT2AMAPTTNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1444210-B1 | QUNAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2009-02-18 | — | — | EP | disclosed |
| US-20070082921-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-12 | — | — | US | disclosed |
| US-20050043336-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-02-24 | — | — | US | disclosed |
| EP-1444210-A1 | QUNAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003040108-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043336-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | MAPK10 1069/4885MEN1 1212/4885KMT2A 1693/4885 |
| US-20070082921-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | MAPK10 803/4885MEN1 2352/4885KMT2A 1786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.